Evaluation of L/N type Ca2+ channel blocker (cilnidipine) in hypertension complicated diabetes or sleep apnea syndrome ; Trial for the effects of improvementof arteriosclerosis and renal function.

Evaluation of L/N type Ca2+ channel blocker (cilnidipine) in hypertension complicated diabetes or sleep apnea syndrome ; Trial for the effects of improvementof arteriosclerosis and renal function. - Study of effects on renal function and blood pressure and hardening of the arteries by Cilnidipine.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014635

Enrollment

Registered

2014-07-24

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes/Hypertension/Sleep apnea syndrome

Interventions

Observation of changes with a cilnidipine administration. Observation of changes with a amlodipine administration.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hypertensive patients not reaching the step-down goal, even the administration of RAS inhibitors for more than three months or no medication. 2) Diabetic nephropathy 3) Patients complicated with sleep apnea syndrome. Among the above-mentioned; 1)+2)+3) or 1)+2) or 1)+3)

Exclusion criteria

Exclusion criteria: 1) Patients with Ca blocker taking. 2) Pregnancy, or patients who are its possible. 3) Patients with a history of hypersensitivity to Ca blocker. 4) Patients the physician judged inappropriate to this study.

Design outcomes

Primary

Measure	Time frame
office blood presure PWV IMT urinary albumin (diabetes only) urinary LFAB-P	—

Secondary

Measure	Time frame
e-GFR adiponectin hs-CRP	—

Countries

Japan

Contacts

Public ContactTakehiko Wago

Kanazawa Medical Clinic/Minatomirai clinic Internal medicine

wagou-endo@umin.ac.jp045-664-6606

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026